Omada Health (NASDAQ:OMDA) Stock: Insider Sean Duffy Sells 12,944 Shares

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,944 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $19.22, for a total value of $248,783.68. Following the sale, the chief executive officer owned 382,594 shares of the company’s stock, valued at approximately $7,353,456.68. This trade represents a 3.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Omada Health Stock Down 20.4%

Shares of OMDA traded down $3.86 during mid-day trading on Friday, hitting $15.09. The stock had a trading volume of 4,708,188 shares, compared to its average volume of 1,269,705. The company has a market cap of $923.76 million, a PE ratio of 301.80 and a beta of 2.13. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $25.45. The company’s fifty day simple moving average is $20.33 and its two-hundred day simple moving average is $17.74.

Omada Health (NASDAQ:OMDA) last posted its earnings results on Thursday, November 5th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The firm had revenue of $91.31 million during the quarter. Equities analysts expect that Omada Health, Inc. will post 0.09 earnings per share for the current year.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada reported Q3 revenue of $91 million, up 34% year over year, and total members grew 36% to a record 1.1 million. Net income was $7 million versus a year-ago loss, while adjusted EBITDA increased to $12 million. The company also raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Positive Sentiment: Quarterly revenue exceeded FactSet’s estimate, and reported earnings also topped consensus estimates, providing evidence of stronger-than-expected operating performance. Earnings Flash: Q3 Revenue
• Neutral Sentiment: Unusual options activity was reported after Omada’s earnings, signaling heightened trading interest but not indicating a clear direction for the stock. Unusual Options Volume Report
• Negative Sentiment: Several analysts took a more cautious stance: Wells Fargo cut its price target to $19 and maintained an “equal weight” rating, while Zacks Research downgraded OMDA from “strong buy” to “hold.” Wells Fargo analyst actions Zacks Research analyst action
• Negative Sentiment: Barclays also lowered its target from $24 to $22, although it retained an “overweight” rating. Barclays analyst action

Analyst Ratings Changes

Several research analysts have recently issued reports on OMDA shares. Barclays dropped their price objective on shares of Omada Health from $24.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday. Citizens Jmp upped their price objective on Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a report on Friday, August 14th. Wells Fargo & Company lowered their target price on Omada Health from $22.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday. Robert W. Baird raised their target price on shares of Omada Health from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Finally, BTIG Research reaffirmed a “buy” rating and set a $35.00 target price on shares of Omada Health in a report on Friday, September 11th. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Omada Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.33.

Institutional Investors Weigh In On Omada Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC lifted its position in Omada Health by 1,161.6% during the 3rd quarter. Sterling Capital Management LLC now owns 1,577 shares of the company’s stock valued at $33,000 after acquiring an additional 1,452 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of Omada Health during the 2nd quarter worth $53,000. State of Alaska Department of Revenue purchased a new position in Omada Health during the third quarter valued at approximately $59,000. Versant Capital Management Inc raised its stake in Omada Health by 319.3% during the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after purchasing an additional 2,283 shares during the period. Finally, Legal & General Group Plc bought a new position in Omada Health during the second quarter valued at approximately $76,000.

About Omada Health

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.